AI Meets CRO: How Charles River and Lilly Are Rewriting Drug Discovery

WILMINGTON, MA – June 18, 2026 – In a move that signals a significant shift in the architecture of modern drug development, Charles River Laboratories has announced a major collaboration with Lilly TuneLab, a cutting-edge artificial intelligence platform from pharmaceutical giant Eli Lilly and Company. The partnership aims to fuse Charles River's decades of expertise in nonclinical testing with TuneLab's powerful machine learning models, creating a synergistic ecosystem designed to accelerate the journey from molecular concept to life-saving therapeutic.

This collaboration goes beyond a simple service agreement. It represents the integration of two critical pillars of the pharmaceutical pipeline: the predictive power of AI and the empirical validation of contract research. For the growing number of biotech companies navigating the high-stakes, capital-intensive world of early-stage discovery, this alliance promises access to tools once reserved for the industry's largest players.

“The combination of Charles River’s decades-long expertise in nonclinical testing with TuneLab’s innovative AI/ML models will support the accelerated development of innovative therapeutics,” said Dr. Namandjé N. Bumpus, Chief Science and Innovation Officer at Charles River. “TuneLab’s collaborative AI platform democratizes access to pharma-grade tools, relieving a substantial resource burden for biotechs. By layering in Charles River’s industry-leading hands-on research experience, TuneLab participants have access to additional validation that supports discovery decision-making.”

A New Synergy: Combining AI Predictions with Real-World Validation

At the heart of this partnership is a powerful feedback loop. Lilly TuneLab provides participating companies with access to sophisticated AI and machine learning models trained on decades of Lilly's proprietary research data—a dataset one industry source estimates represents over $1 billion in compilation costs. These models help scientists predict a drug candidate's properties, such as its safety profile and how it will be absorbed, distributed, metabolized, and excreted (ADME), allowing them to more rapidly down-select the most promising molecules for further study.

The platform operates on a federated learning model, a privacy-preserving technique that allows participating companies to contribute their own data to improve the collective AI models without ever exposing their proprietary information to Lilly or other partners. This creates a continuously improving intelligence hub.

This is where Charles River's role becomes transformative. As a leading global contract research organization (CRO), it will provide the nonclinical testing services for companies within the TuneLab ecosystem. By standardizing the testing protocols used to generate this new data, the collaboration ensures that the information fed back into TuneLab’s AI is consistent, high-quality, and structured for maximum impact. This structured, real-world validation sharpens the AI's predictive accuracy, creating a virtuous cycle where better data leads to better models, which in turn lead to better drug candidates being selected for testing.

Democratizing Innovation in the Biotech Ecosystem

For small and emerging biopharmaceutical companies, the early stages of drug discovery are a formidable challenge. They often operate with lean teams and limited capital, making it nearly impossible to build the large-scale, high-quality datasets needed to train effective AI models from scratch. This partnership directly addresses that hurdle.

By providing access to Lilly's pre-trained models and Charles River's established testing infrastructure, the collaboration effectively levels the playing field. It compresses what Lilly describes as “decades of learning into instantly accessible intelligence,” allowing smaller innovators to focus their resources on novel science rather than on building foundational capabilities.

This initiative is a key component of Lilly Catalyze360, a broader strategy to nurture the external biotech landscape. Catalyze360 aims to be a one-stop shop for innovation, offering not just AI tools through TuneLab but also strategic capital via Lilly Ventures, accelerator lab space through Lilly Gateway Labs, and development expertise from Lilly ExploR&D. This ecosystem approach underscores a fundamental shift in big pharma's strategy: rather than solely relying on internal R&D, industry leaders are now building platforms to cultivate and capture innovation from a global network of smaller, more agile partners. The inclusion of other collaborators, such as Circle Pharma and the integration with platforms like Collaborative Drug Discovery's CDD Vault, demonstrates the growing momentum behind this open, ecosystem-driven model.

Beyond the Lab: Advancing Ethical and Efficient Drug Development

This partnership isn’t just about making drug discovery faster and cheaper; it’s also about making it smarter and more responsible. Charles River has been a vocal proponent of reducing the industry's reliance on traditional animal testing through its Alternative Methods Advancement Project (AMAP). With a planned investment totaling $500 million, AMAP is dedicated to developing and validating New Approach Methodologies (NAMs)—such as advanced in vitro models, organ-on-a-chip technologies, and computational approaches—that can provide human-relevant data while upholding ethical commitments.

The synergy with TuneLab aligns perfectly with this mission. By using AI to better predict a molecule's potential for toxicity or lack of efficacy early on, researchers can avoid pursuing unpromising candidates, thereby reducing the number of costly and ethically sensitive animal studies required down the line. This approach is gaining significant traction with regulatory bodies. In January 2026, the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) jointly published guiding principles on the use of AI in drug development, explicitly noting that these technologies are anticipated to help decrease the reliance on animal testing.

These regulatory frameworks emphasize the need for robust data governance, human oversight, and a clear understanding of an AI model's context of use—principles that are foundational to the TuneLab and Charles River collaboration. By building a system grounded in high-quality data and transparent validation, the partners are not only accelerating innovation but also helping to define the gold standard for responsible AI implementation in medicine.

Charting a New Course in a Competitive Landscape

Eli Lilly and Charles River are not alone in the race to integrate AI into drug discovery. Other pharmaceutical giants like Roche are deploying “lab in a loop” strategies, and a host of AI-native companies such as Insilico Medicine and Recursion are already advancing AI-discovered molecules into clinical trials. The field is crowded and moving at a breakneck pace.

However, the Charles River-Lilly partnership carves out a unique position. Its distinction lies in the tight, symbiotic integration of three core elements: a major pharma's deep, proprietary dataset; a state-of-the-art federated AI platform; and the standardized, world-class nonclinical testing infrastructure of a leading CRO. This creates an end-to-end solution that is difficult for competitors to replicate, offering biotechs not just a predictive tool, but a clear, validated path forward.

For Lilly, the collaboration enriches its Catalyze360 ecosystem, turning it into a powerful engine for external innovation. For Charles River, it embeds its essential services at the heart of a next-generation discovery workflow, solidifying its role as a critical partner in the future of data-driven medicine. This alliance represents more than a headline-grabbing deal; it is a blueprint for a new industrial paradigm, where collaboration and data sharing—once anathema in a secretive industry—are becoming the primary drivers of progress.